COHORT Aktie

 

Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test Survey findings show eligible individuals prefer a blood test for colorectal cancer and lung cancer compared with traditional screening methods PALO ALTO, Calif.--(BUSINESS WIRE)--$GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showing the critical role of blood-based testing in increasing cancer screening adherence at the American College of Gastroenterology (ACG) 2025 Annual Meeting in Phoenix, Arizona taking place Friday, October 24 – Wednesday, October 29, 2025. Building off findings from Guardant Health's 2023 ACG abstract, a study of an expanded cohort of 20,000 patients confirmed findings from earlier reports on the effectiveness of the Shield blood-based screening test in improving adherence to colorectal cancer (CRC) screening. Shield is the first and only blood test to re...

Americans' property-tax bills have risen sharply in recent years. But the newest cohort of homeowners — particularly those who bought newly constructed homes — may be facing the biggest payment shocks of all....

AUSTIN, Texas, Oct. 23, 2025 /PRNewswire/ -- PeopleFund a Texas non-profit small business lender, the Veterans Business Outreach Center University of Texas at Arlington (UTAVBOC) and the Veteran Women's Enterprise Center (VWEC), proudly announced the graduation of the inaugural......

As WealthTech enters a new phase, The Founders Arena kicks off its third year with six startups applying AI with purpose ARLINGTON, Texas, Oct. 22, 2025 /PRNewswire/ -- The Founders Arena, the leading global WealthTech Accelerator, in collaboration with First Rate, Inc., SEI®, the City of......

WORCESTER, Mass., Oct. 21, 2025 /PRNewswire/ -- Assumption University is advancing educational opportunities for healthcare professionals and receiving national recognition for academic and programmatic excellence. In January, Assumption welcomed its first cohort of 40 physician assistant......

Shares of Beyond Meat Inc. are soaring this week amid speculation that the struggling maker of pea-based meat substitutes might be joining the latest cohort of meme stocks....

Following groundbreaking initial results, MoreBetter announces the second study cohort with 10 new brands, 15+ SKUs, and 2,000+ new participants to deepen understanding of real-world wellness impacts. PHILADELPHIA, Oct. 21, 2025 /PRNewswire/ -- After uncovering compelling evidence that......

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce a collaboration with Memorial Sloan Kettering Cancer Center's (MSK's) Therapeutics Accelerator Cohort program to accelerate the clinical development of Bria-OTS+, BriaCell's next generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers....

Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the enrollment of the last patient for the first cohort of its Phase I/IIa clinical trial evaluating CMND-100, the Company's proprietary MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD)....

Synartro AB announces that it has completed the treatment of the second out of four participant cohorts in its phase 1/2a clinical study of SYN321. The third cohort is to be dosed within the coming weeks. Synartro's investigational drug SYN321 is a novel joint injection treatment targeting symptoms of knee osteoarthritis. The purpose of the ongoing phase 1/2a study is to evaluate safety and tolerability, as well as to obtain exploratory efficacy data. The first study participant was dosed on September 1st, 2025 and the study is expected to be completed in the spring of 2026. It is conducted...

INDIANAPOLIS, Oct. 20, 2025 /PRNewswire/ -- Plug and Play, the world's largest innovation platform, today announced the 12 companies selected for the inaugural batch of its Lifetech accelerator program in Indianapolis. The cohort draws from a global talent pool and represents startup......

Futures Rise As Trade, Credit Fears Fade Ahead Of Earnings Deluge US equity futures are higher led by small caps, with sentiment TACOed for a second consecutive weekend thanks to Trump's comments that the US will “be fine” with China ahead of trade talks between the two sides. It's going to be a busy week for earnings, with Tesla, Netflix and General Motors among companies reporting. As of 8:00am, S&P futures are up 0.3%, with Nasdaq futures up 0.4%. Pre-mkt, Mag7 names are all higher; Tesla climbed in pre-market trading ahead of its report Wednesday, the first from the Magnificent Seven cohort of big-tech companies. There are also notable moves higher in Fins as credit concerns subside. Treasuries, which rallied last week amid trade-war and credit quality jitters, are steady today around 4.00% on the 10Y. The yield curve is flatter with 2Y and 5Y yield higher, while 10Y yields are mostly unchanged at 4.00%. Ahead of a resumption in US/China talks this week in Malaysia, Trump said r...

Endeavor Health, Henry Ford Health, Lurie Children's Hospital of Chicago, Nemours Children's Health, Northwestern Medicine, and Rush Health sign on to build high value companies that benefit both healthcare providers and families. CHICAGO, Oct. 20, 2025 /PRNewswire/ -- Six months after......

Summit Plans to Submit a BLA in Q4 2025 for Ivonescimab Based on HARMONi Global Phase III Study Results Expansion of Summit's Global Phase III Development Program Starts with Initiation of HARMONi-GI3, a New Study in 1L CRC: Summit to Initiate an Additional Set of Phase III Clinical Trials with Details to Come in Q1 2026 Ivonescimab with Chemotherapy Reduces the Risk of Disease Progression or Death by 48% Compared to Chemotherapy Alone in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy with Consistent Data across Regions Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40%, Median PFS of 11.14 Months, Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy, Median PFS 6.90 Months, in 1L Treatment of Patients with Squamous NSCLC in Phase III HARMONi-6 Study Conducted by Akeso in China HARMONi-3 Global Phase III Study Analyses Will Be Split by Histology: Squamous NSCLC Cohort Expected to Complete Enrollment First Half of 2026 w...

WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European Society for Medical Oncology (ESMO) Congress 2025 being held in Berlin (Poster 1644P)....

WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) released updated results from cohort B2 of its Phase 1/2 RAINFOL-01 clinical trial, evaluating rinatabart sesutecan (Rina-S), an investigational antibody-d......

Encouraging preliminary activity observed across diverse set of advanced ALK-positive solid tumors Global enrollment ongoing for adult and adolescent patients with advanced ALK-positive solid tumors beyond NSCLC in a Phase 2 cohort of the ALKOVE-1 trial CAMBRIDGE, Mass., Oct. 18, 2025......

MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in adults with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-“), PIK3CA WT, advanced breast cancer (“ABC”), following progression on, or after, treatment with a CDK4/6 inhibitor and an aromatase inhibitor. As previously announced, the gedatolisib triplet demonstrated a statistically significant and clinically meaningful improvement in median progression-free survival (“PFS”) versus fulvestrant, reducing the risk of disease progression or death by 76%. The gedatolisib doublet reduced the risk of progression or death by 67% versus fulvestrant....

MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updates on the status of the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with and without palbociclib versus alpelisib and fulvestrant in adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA mutant (“MT”) tumors, locally advanced or metastatic breast cancer, following progression on, or after, treatment with a CDK4/6 inhibitor and an aromatase inhibitor. Analysis of data from a Phase 1b clinical trial that evaluated gedatolisib combined with palbociclib and fulvestrant in the same population was also provided....

BOSTON, Oct. 16, 2025 /PRNewswire/ -- LearnLaunch Fund + Accelerator will bring select portfolio companies and partners to EDTECH WEEK in New York City, October 20–22. For Cohort 15 startups, the event marks the culmination of the accelerator experience, providing opportunities to engage......